ASA. S. Semikhin

A. S. Semikhin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


A. S. Semikhin has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outbreaks of tularemia in Russia (1997–2023)

    by T. N. Demidova, T. V. Mikhailova, A. S. Semikhin, D. V. Tranquilevsky, E. A. Gurina, N. V. Sheenkov

    Relevance. Currently, much attention is paid worldwide to diseases transmitted by vectors (bites of ticks, mosquitoes and horseflies). In our country, at least nine pathogens of zoonotic infections transmitted by this route are registered: tularemia, borreliosis, tickborne encephalitis, anaplasmosis, rickettsiosis, Q fever, babesiosis, bartonellosis and ehrlichiosis. In Russia, outbreaks of tularemia associated with the transmission of infection through bites of blood-sucking arthropods have increased, and waterborne and trench epidemic outbreaks have also been registered. Waterborne outbreaks are associated with the use of water contaminated with corpses or excrements from sick rodents. Trench outbreaks are associated with the mass settlement of military structures by rodents, in whose populations epizootics occur.Goal Target. Determination of the epidemiological type of outbreak morbidity and the possibility of its elimination. Materials and methods. The materials were statistical data of Rospotrebnadzor on the incidence of tularemia, the volume of vaccination against this infection. Retrospective data on morbidity and epizootological studies from the archives of the Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation for 1997–2023, 375 cards of epidemiological investigations of tularemia cases were used. Reports of epizootological surveys of focal areas of the regions of the Russian Federation were analyzed.Results and discussion. In the territory of the Federal Districts of Russia from 1997 to 2023 inclusive, 61 epidemic outbreaks of tularemia from 10 to 955 cases were registered, including 52 transmissible in the Central Federal District (13), Northwestern Federal District (18), Ural Federal District (5), Siberian Federal District (9), Volga Federal District (6) and Far Eastern Federal District (1). The total number of cases during the outbreaks was 3261 patients with tularemia, of which: 2754 cases of diseases from bites of blood-sucking arthropods (transmissive type of disease), 254 people fell ill after drinking raw water (water type of disease), 253 people fell ill while in trenches (trenches), where there was a large accumulation of rodents (trench type of disease). Bubonic and ulcerative-bubonic clinical forms of tularemia are typical for transmission through horseflies and mosquitoes, and when an insect gets into the eye, the ocular-bubonic form. Waterborne outbreaks of tularemia occur when drinking or washing with water. The main clinical forms of this type of disease are angina-bubonic, abdominal and ocular-bubonic, sometimes mixed - abdominal + angina. In the trench type of infection, pulmonary with bronchitis and pneumonic variants (thoracic), angina-bubonic (anginal-glandular) and abdominal (gastrointestinal) clinical forms of tularemia prevailed. The cause of the outbreak was a combination of natural factors, lack of immunity in the population and insufficient awareness of the etiological diagnosis of the infection. With the cessation of human morbidity, the natural focus of tularemia does not cease to exist, and with a decrease in the number of vaccinated, and therefore susceptible to the pathogen, a threat of a new outbreak arises.Conclusions. In order to ensure epidemiological well-being in terms of tularemia, it is necessary to maintain the level of vaccination and revaccination within 2.5–3 million per year of contingents subject to vaccination, taking into account the degree of epizootic activity of natural foci. Epidemic outbreaks of tularemia may occur against the background of a significant decrease in the volume of vaccination of the population living in areas enzootic for this infection. Tularemia is characterized by polymorphism of clinical manifestations, therefore, a carefully collected epidemiological history is of great importance for the diagnosis of this infection. It is necessary to conduct explanatory work on preventive measures among the population living in areas endemic for tularemia in connection with multiple refusals of vaccination against tularemia. It is necessary to carry out measures to improve the sanitary and epidemiological literacy of doctors regarding tularemia infection.

  • Open Access

    Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia

    by Dy Logunov, Dolzhikova, My Boiro, Av Kovyrshina, As Dzharullaeva, As Erokhova, Dm Grousova, Ai Tukhvatulin, Fm Izhaeva, Yv Simakova, et al.

    Ebola virus disease (EVD) is one of the most dangerous and lethal diseases affecting humans. There are several licensed vaccines against EVD, but it remains one of the priority diseases for research and development of effective vaccines. A double-blind randomized placebo-controlled trial was performed to evaluate safety and immunogenicity of rVSV- and rAd5-vectored vaccine “GamEvac-Combi” in healthy adults of both sexes between 18 and 60 years. Safety and immunogenicity were assessed during the observation period of 12 months. Immunogenicity was assessed with GP-specific ELISA, IFN-γ ELISA, and plaque pseudoneutralization assay. Vaccinated participants showed marked GP-specific IFN-γ response at day 28 and neutralizing response at day 42 (GMT = 32.6, seroconversion rate 96.3%). GP-specific IgG antibody levels in vaccinated participants peaked at day 42 (GMT = 9345) and persisted for a year after vaccination (GMT = 650). The vaccine showed favorable safety profile and induced robust cell-mediated immune response and strong humoral immune response that lasts at least for a year from the start of vaccination. The study was funded by the Ministry of Health of Russian Federation; GamEvac-Combi ClinicalTrials.gov number, NCT03072030 , Pan African Clinical Trial Registry PACTR201702002053400.

  • Open Access

    The Epidemic Situation of Tularemia in Karelia at the Present Time

    by T. N. Demidova, L. V. Rubis, A. S. Semikhin, E. A. Gurina, A. V. Amirkhanyan, N. V. Sheenkov, V. V. Gorshenko, Yu. A. Birkovskay

    Tularemia is a natural focal infection, characterized by the ability to maintain epizootic and epidemic potential for decades and periodically become more active. Since 2016, an increase in the incidence of tularemia has been observed in the Republic of Karelia.Aims. To evaluate the epidemiological situation with tularemia in the Republic of Karelia to determine the directions of preventive work in modern conditions.Conclusions. Analysis of the epizootic and epidemiological situation regarding tularemia in the Republic of Karelia demonstrates the possibility of intensifying the epizootic process after decades of relative prosperity. The increase in the incidence of the population was not only the result of the activation of natural foci of infection, but also of improved diagnosis of the disease and change in tactics for using vaccines in areas enzootic for tularemia.


  • Open Access

    Real clinical practice of infertility treatment in Russia: a collective opinion of 425 reproductologists

    by N. V. Bashmakova, E. N. Novoselova, T. A. Nazarenko, M. M. Ovchinnikova, Yu. A. Fetisova, E. V. Gergert, M. A. Ganikhina, N. G. Valiullina, E. O. Golovina, M. R. Shcherban, et al.

    Introduction. Approaches to treatment of infertility have been progressively updated because the field of assisted reproductive technologies (ART) is a science-based symbiosis of the latest knowledge and advances in medicine, biology, and genetics. Today, a real-world clinical practice of a reproductive specialist needs to be assessed in the Russian Federation (RF) both in terms of a retrospectively analyzed development of RF in vitro fertilization (IVF) technologies and identifying promising approaches for infertility treatment in the future.Aim: analysis of current therapeutic tendencies and promising trends in real clinical practice of infertility in the Russian Federation.Materials and Methods. In 2022–2023 under the auspices of the Institute for Preventive and Social Medicine and the National Alliance for Public Health Advancement, a survey of reproductive doctors practicing at commercial and government ART centers was carried out. The questionnaire contained questions regarding describing a RF female patient’s portrait with an expected ovarian reserve and response to ovarian stimulation to propose a choice of ovarian stimulation protocol as well as basic and concomitant pharmacotherapy.Results. The opinion of 425 fertility doctors from 156 ART centers in 42 cities of the Russian Federation was assessed. A portrait of a female patient with infertility in the Russian Federation was determined in accordance with the ovarian reserve, expected response to gonadotropin-based stimulation (normal response – 40 %, hyporesponse – 40 %, hyperresponse – 20 % of patients). The basic pharmacotherapy in the stimulation protocol in the IVF program based on agonists and antagonists of gonadotropinreleasing hormone (GnRH), various gonadotropin-containing drugs in female patients with expected normal, hypo- and hyperresponse to ovarian stimulation was assessed. The dominant protocol consists of using GnRH antagonist most often observed in patients with hyper- (95 % of cases), normal (75 % of cases) and hypo-response (45.5 %). Preferences in the basic and concomitant pharmacotherapy in IVF programs were identified as well as current trends in embryo transfer in fresh and cryoprotocols (a tendency to freeze all obtained embryos - “freeze-all” strategy), preimplantation genetic testing methods (used in 30 % of protocols in normal responders, 60 % in hyporesponders and 10 % in hyperresponders) were described.Conclusion. Our study provides the most large-scale analysis of the real-world clinical practice of RF reproductive specialists. A portrait of a RF female patient with infertility, expected ovarian reserve and response to ovarian stimulation was described. Contemporary approaches to select stimulation protocol, basic and concomitant pharmacotherapy in real-world clinical practice were identified. The data obtained represent an important significant cross-section for current practical approaches in real-world practice of RF fertility doctors and can serve as the basis for assessing developing ART methods in the Russian Federation as well as be used to create an evidence base for analyzing future clinical and economic effectiveness of IVF programs in the Russian Federation.


  • Open Access

    Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022

    by D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin

    Objective: to perform a clinical and economic analysis of using drugs containing follitropin alfa as an active substance and to assess the impact of the studied drugs on the budget of the state healthcare system of the Russian Federation considering cost data for 2022 in the population of women with infertility and poor ovarian response who are undergoing treatment with the use of assisted reproductive technologies (ART).Material and methods. Clinical and economic evaluation of follitropin alfa use in patients with infertility and poor ovarian response was performed by a cost minimization method, using data from the Uniform Information System for Procurement for the period from July to December 2022 inclusive. The budget impact analysis model compared the costs required for ovarian stimulation of patients with poor ovarian response receiving only a fixed dose combination (FDC) of follitropin alfa + lutropin alfa with the expected practice of switching 25% of these patients to follitropin alfa with a modeling time horizon of 1 year.Results. A cost analysis of an ovarian stimulation course using biosimilar follitropin alfa showed cost savings of 17% compared with the cost of therapy using the original follitropin alfa. Also, cost minimization analysis per cycle of ovarian stimulation demonstrated that the use of the biosimilar follitropin alfa was characterized by cost savings of 24,420 rubles (32.37%) compared to FCD of follitropin alfa + lutropin alfa. Compared to the 2021 data, in the current study based on 2022 data and including only biosimilar follitropin alfa, there was a 103% increase in savings. Budget impact analysis determined that switching 25% of the population from FCD of follitropin alfa + lutropin alfa to follitropin alfa would reduce direct medical costs by 17.3 million rubles (8.1%) per year. Savings in direct medical costs in the current study compared to 2021 increased by 117%.Conclusion. The clinical and economic analysis, as well as the budget impact analysis of using biosimilar follitropin alfa for ovarian stimulation in a population of women with infertility and poor ovarian response, confirm the economic expediency revealed in 2021. Moreover, according to 2022 data, the use of biosimilar follitropin alfa results in additional budgetary savings.


  • Open Access

    Combined Foci of Tularemia, Leptospirosis and Hemorrhagic Fever with Renal Syndrome in the South of the Arkhangelsk region

    by T. V. Mikhailova, L. G. Emelyanova, Y. S. Podobedova, T. N. Demidova, M. I. Kormilitsyna, A. S. Semikhin, A. V. Amirkhanyan, N. E. Sharapova, O. V. Savelyeva, Y. V. Popova

    Relevance. Combined foci of zoonotic infections are found in all regions of the Russian Federation. A feature of combined foci is the common biocenosis for populations of pathogens of various etiologies (bacteria, viruses, parasitic infections) and the formation of natural foci by them. Aim. Epizootological study of the territory in the south of the Arkhangelsk region for the presence of combined foci of zoonotic infections (tularemia, leptospirosis and hemorrhagic fever with renal syndrome – HFRS). Materials and methods. 135 small mammals were captured and examined in the Ustyansky district of the Arkhangelsk region. Established the species composition and mixed infection among small mammals pathogens of tularemia, leptospirosis, hemorrhagic fever with renal syndrome. Results. In the south of the Arkhangelsk Region in the Ustyansky District, in 2019, for the first time, a combined natural focus of the forest type was identified and characterized. The bank vole and the common shrew are the main carriers of the causative agents of these infections. Five species of small mammals are mixed-infected with the causative agents of these infections. Infected animals with one, two or three pathogens were simultaneously detected in all studied biotopes. This indicates the presence of a combined natural focus of tularemia, leptospirosis, and HFRS. Conclusion. The existence of a combined natural focus of tularemia, leptospirosis and HFRS in middle taiga ecosystems in the south in the Ustyansky district of the Arkhangelsk region was revealed for the first time. Thus, this area can be considered enzootic for tularemia, leptospirosis and HFRS. This focus belongs to the forest type in terms of landscape and geographical characteristics. Mixed infection of small mammals suggests the possibility of simultaneous infection with pathogens of two or more infections, not only animals, but also people located on the territory of natural foci. and non-simultaneous infection of humans with tularemia, leptospirosis and HFRS in combined foci.


  • Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)

    by E.I. Gusev, M.YU. Martynov, N.A. Shamalov, E.B. Yarovaya, M.P. Semenov, A.M. Semenov, A.A. Orlovsky, V.A. Kutsenko, A.A. Nikonov, S.B. Aksentiev, et al.

    ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение эффективности и безопасности неиммуногенной стафилокиназы (НС) в сравнении с алтеплазой (А) у пациентов с ишемическим инсультом (ИИ) в первые 4,5 ч от развития симптомов. МАТЕРИАЛ И МЕТОДЫ В открытом рандомизированном сравнительном исследовании «не меньшей эффективности» в параллельных группах НС и А приняли участие 336 пациентов (по 168 в каждой группе) в первые 4,5 ч ИИ. НС вводилась в дозе 10 мг вне зависимости от массы тела внутривенно болюсно в течение 10 с, А — болюсно-инфузионно в дозе 0,9 мг/кг (максимально 90 мг) в течение 1 ч. Первичной конечной точкой эффективности считался благоприятный исход — 0—1 балл по модифицированной шкале Рэнкина (mRS) на 90-й день после введения препаратов. Конечные точки безопасности включали смертность от всех причин на 90-й день, симптомное внутричерепное кровоизлияние и другие серьезные нежелательные явления (СНЯ). РЕЗУЛЬТАТЫ К 90-му дню заболевания первичную конечную точку в группе НС достигли 84 (50%) пациента, в группе А — 68 (41%) (p=0,10, ОШ=1,47, 95% ДИ=0,93—2,32). Разница между группами НС и А составила 9,5% (95% ДИ= –1,7—20,7), и левая граница 95% ДИ не пересекала границу «не меньшей эффективности» (p«не меньшей эффективности»p=0,32). Частота симптомных внутричерепных кровоизлияний была несколько реже в группе НС — 5 (3%) пациентов, в группе А — 13 (8%) (p=0,087, ОШ=0,37, 95% ДИ=0,1—1,13). СНЯ в группе НС развились у 22 (13%) пациентов, в группе А — у 37 (22%) (p=0,044, ОШ=0,53, 95% ДИ=0,28—0,98). ЗАКЛЮЧЕНИЕ Результаты исследования ФРИДА являются первыми в мире по применению препарата на основе НС у пациентов с ИИ. Показано, что однократное болюсное введение НС в стандартной дозе в 10 мг вне зависимости от массы тела позволяет быстро, эффективно и безопасно проводить тромболитическую терапию у пациентов с ИИ в течение 4,5 ч от начала заболевания. В дальнейших клинических исследованиях НС планируется расширение терапевтического окна в 4,5 ч после появления симптомов у пациентов с ИИ.